JP2020535232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535232A5 JP2020535232A5 JP2020538776A JP2020538776A JP2020535232A5 JP 2020535232 A5 JP2020535232 A5 JP 2020535232A5 JP 2020538776 A JP2020538776 A JP 2020538776A JP 2020538776 A JP2020538776 A JP 2020538776A JP 2020535232 A5 JP2020535232 A5 JP 2020535232A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- surfactant
- octreotide
- permeation enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 68
- 239000004094 surface-active agent Substances 0.000 claims description 23
- 239000003961 penetration enhancing agent Substances 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 15
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 14
- 108010016076 Octreotide Proteins 0.000 claims description 14
- 229960002700 octreotide Drugs 0.000 claims description 14
- -1 glycine betaine ester Chemical class 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 229960003237 betaine Drugs 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 125000004450 alkenylene group Chemical group 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000000693 micelle Substances 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 229920000715 Mucilage Polymers 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000002532 enzyme inhibitor Substances 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 230000004136 fatty acid synthesis Effects 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 230000003232 mucoadhesive effect Effects 0.000 claims description 2
- 229940066491 mucolytics Drugs 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 230000035790 physiological processes and functions Effects 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 208000020475 growth hormone-producing pituitary gland neoplasm Diseases 0.000 description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010018758 Growth hormone-producing pituitary tumour Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 201000010430 hormone producing pituitary cancer Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024108581A JP2024156672A (ja) | 2017-09-26 | 2024-07-05 | 透過エンハンサーを含む送達医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563534P | 2017-09-26 | 2017-09-26 | |
| US62/563,534 | 2017-09-26 | ||
| PCT/US2018/052927 WO2019067596A1 (en) | 2017-09-26 | 2018-09-26 | ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS CONTAINING PERMEATION PROMOTERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108581A Division JP2024156672A (ja) | 2017-09-26 | 2024-07-05 | 透過エンハンサーを含む送達医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535232A JP2020535232A (ja) | 2020-12-03 |
| JP2020535232A5 true JP2020535232A5 (https=) | 2021-11-11 |
Family
ID=63858155
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538776A Pending JP2020535232A (ja) | 2017-09-26 | 2018-09-26 | 透過エンハンサーを含む送達医薬組成物 |
| JP2024108581A Pending JP2024156672A (ja) | 2017-09-26 | 2024-07-05 | 透過エンハンサーを含む送達医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108581A Pending JP2024156672A (ja) | 2017-09-26 | 2024-07-05 | 透過エンハンサーを含む送達医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190091281A1 (https=) |
| EP (1) | EP3687508A1 (https=) |
| JP (2) | JP2020535232A (https=) |
| KR (1) | KR20200059269A (https=) |
| CN (1) | CN111148512A (https=) |
| BR (1) | BR112020005875A2 (https=) |
| CA (1) | CA3076751A1 (https=) |
| IL (2) | IL273477B2 (https=) |
| WO (1) | WO2019067596A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313551A (en) * | 2017-09-27 | 2024-08-01 | Aquestive Therapeutics Inc | Enhanced delivery epinephrine and prodrug compositions |
| US11648197B2 (en) | 2018-06-28 | 2023-05-16 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
| US12440472B2 (en) * | 2021-06-16 | 2025-10-14 | Intelgenx Corp. | Stable tryptamine oral films |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8620035D0 (en) * | 1986-08-18 | 1986-10-01 | Sandoz Ltd | Organic compounds |
| GB2193891B (en) * | 1986-08-18 | 1990-07-25 | Sandoz Ltd | Nasal pharmaceutical composition containing a somatostatin anologue. |
| US5879690A (en) * | 1995-09-07 | 1999-03-09 | Perricone; Nicholas V. | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
| US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| SE0302924D0 (sv) * | 2003-11-05 | 2003-11-05 | Camurus Ab | Pharmaceutical composition having a cationic excipient |
| US20110257096A1 (en) * | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US20060073173A1 (en) * | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
| ZA200711040B (en) * | 2005-06-03 | 2009-04-29 | Acrux Dds Pty Ltd | Method and composition for transdermal drug delivery |
| WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| GB2478849A (en) * | 2010-03-16 | 2011-09-21 | Chiasma Inc | Improved pharmecutical compositions and methods of delivery |
| IE20100174A1 (en) * | 2010-03-25 | 2012-02-29 | Trinity College Dublin | Transdermal administration of peptides |
| WO2012070028A1 (en) * | 2010-11-26 | 2012-05-31 | University Of The Witwatersrand, Johannesburg | A pharmaceutical dosage form |
| KR20150027831A (ko) * | 2012-07-06 | 2015-03-12 | 레오 파마 에이/에스 | 피부에 활성 성분을 전달하기 위한 막-형성 중합체를 포함하는 국소 조성물 |
| FR3013589B1 (fr) * | 2013-11-28 | 2017-03-31 | Soc D'exploitation De Produits Pour Les Ind Chimiques Seppic | Composition d'alkyl polyglucosides et d'acides gras cationisees |
| US20170119660A1 (en) * | 2015-10-29 | 2017-05-04 | Solubest Ltd | Pharmaceutical compositions for transmucosal delivery |
-
2018
- 2018-09-26 EP EP18786579.5A patent/EP3687508A1/en active Pending
- 2018-09-26 CN CN201880062678.9A patent/CN111148512A/zh active Pending
- 2018-09-26 JP JP2020538776A patent/JP2020535232A/ja active Pending
- 2018-09-26 CA CA3076751A patent/CA3076751A1/en active Pending
- 2018-09-26 IL IL273477A patent/IL273477B2/en unknown
- 2018-09-26 BR BR112020005875-0A patent/BR112020005875A2/pt unknown
- 2018-09-26 IL IL311142A patent/IL311142A/en unknown
- 2018-09-26 WO PCT/US2018/052927 patent/WO2019067596A1/en not_active Ceased
- 2018-09-26 KR KR1020207011909A patent/KR20200059269A/ko active Pending
- 2018-09-26 US US16/143,036 patent/US20190091281A1/en active Pending
-
2024
- 2024-07-05 JP JP2024108581A patent/JP2024156672A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2826468C (en) | Polymer-carbohydrate-lipid conjugates | |
| CA2127805C (en) | Composition for nasal administration | |
| JP2020535232A5 (https=) | ||
| ES2834006T3 (es) | Preparados farmacéuticos a base de lípidos para aplicación tópica | |
| AU2011227083B2 (en) | Stable bortezomib formulations | |
| AU2012215383B2 (en) | Novel antifungal composition | |
| CA2433037A1 (en) | Sustained-release preparation | |
| WO1988004556A1 (en) | Nasal formulations and a process for preparation thereof | |
| US20130267585A1 (en) | Pharmaceutical composition having a cationic excipient | |
| EP1317921A1 (fr) | Composition pharmaceutique sous forme de gel ou de solution à base de dihydrotestostérone, son procédé de préparation et ses utilisations | |
| HUP9902655A2 (hu) | Sündisznófehérjéket tartalmazó gyógyászati készítmény és felhasználása | |
| EP2828297A1 (fr) | Oligosaccharides fonctionnalisés | |
| EP2920200A1 (fr) | Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques | |
| CN117715612A (zh) | 包括掺杂硅颗粒的组合物以及相关方法 | |
| RU2004133349A (ru) | Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата | |
| IL273477B1 (en) | Administration of pharmaceutical preparations including penetration enhancers | |
| JPWO2007136134A1 (ja) | 疎水性薬物内包ポリマーミセルの製造方法 | |
| CN101450213A (zh) | 大豆蛋白药物凝胶剂及其制备方法 | |
| IL175805A0 (en) | Pharmaceutical formulations for the sustained release of interferons and therapeutic applications thereof | |
| CN100371018C (zh) | 降钙素组合物 | |
| Paolino et al. | Polymers-based devices for dermal and transdermal delivery | |
| JPH0691820B2 (ja) | アミノアシラ−ゼ溶液の安定化法 | |
| WO2008068885A1 (ja) | 凍結乾燥用保護剤及び生理活性物質の製造方法 | |
| HK40008037A (en) | Novel antifungal composition | |
| EP3377038A1 (fr) | Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique |